Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Results of Paper-Based Inspection of Japan’s Application for Membership in PIC/S to Be Reported Next May
October 10, 2012
- Dr Takenaka Tapped as NIBIO Advisor, Committed to Creation of Drug Discovery Network
October 9, 2012
- Senior Vice Minister of Health Sakurai Stresses Need to Rebuild Ties with JMA
October 9, 2012
- Health Minister Mitsui Hopes to Ban All Forms of Dispensing Point Services Including Those Using Credit Cards
October 9, 2012
- MHLW to Request Development of 5 Drugs/Indications Determined to Have Unmet Medical Needs
October 5, 2012
- Ministry-Wide Discussions on Generics Necessary: Parliamentary Secretary Umemura
October 4, 2012
- Senior Vice Minister Sakurai Calls for Industry-Growth Perspective on Long-Listed Drug Pricing
October 4, 2012
- MHLW Issues Notification for Precautions in Use of Methapain
October 4, 2012
- Minister of Health Mitsui Sees Need for Cross-Agency Efforts to Promote New Drug Development
October 4, 2012
- MHLW to Enhance Drug Review System to Eliminate Application Lag: PFSB Director Gen. Ebata
October 3, 2012
- Committee to Discuss Basic Policy for Improving Safety and Supply of Blood Products for Its Revision in FY2013
October 3, 2012
- MHLW Issues Improvement Order to Benesis Due to Tampering of Packaging Boxes after Permitting Shipment
October 2, 2012
- Pharmacist Mitsui Becomes Health Minister, Industry Hails Appointment
October 2, 2012
- MHLW Approves 26 Products Including Novartis’s Seebri
October 2, 2012
- Perpetuation of Premium for New Drug Development Will Depend on Convincing Data: HIB Director General Kikura
October 2, 2012
- Study Group Outlines Plan to Establish Palliative Care Centers at Designated Cancer Treatment Alliance Hospitals
October 1, 2012
- MHLW Reports Package Insert Revisions for Elplat
September 28, 2012
- Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
- MHLW Asks FPMAJ to Revise Precaution Section of Package Inserts for 13 APIs Including Diclofenac
September 28, 2012
- HSB to Make “Steady Efforts” Against Lifestyle Diseases: Director General Yajima
September 28, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…